Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.
about
The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs.Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.
P2860
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Genetic and immune factors und ...... metastatic colorectal cancer.
@ast
Genetic and immune factors und ...... metastatic colorectal cancer.
@en
type
label
Genetic and immune factors und ...... metastatic colorectal cancer.
@ast
Genetic and immune factors und ...... metastatic colorectal cancer.
@en
prefLabel
Genetic and immune factors und ...... metastatic colorectal cancer.
@ast
Genetic and immune factors und ...... metastatic colorectal cancer.
@en
P2860
P356
P1476
Genetic and immune factors und ...... metastatic colorectal cancer.
@en
P2093
Dariusz M Kowalski
Paweł Adam Krawczyk
P2860
P356
10.5114/WO.2013.38566
P577
2013-11-14T00:00:00Z